期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (6)
As biologic drugs are gaining attention worldwide, the biopharmaceutical industry in China has developed rapidly in recent years. The People's Republi......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (4)
The early dispute resolution mechanism created a new foundation for pharmaceutical innovation and expanding access to generics in China. This article ......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (1)
Moderna has sublicensed multiple patents owned by Arbutus relating to stable nucleic acid-lipid particles (SNALP), a nucleic acid delivery system usef......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (6)
In the era of smart health care, artificial intelligence technology has penetrated the medical field, resulting in a number of new inventions with dis......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (6)
The claims at issue in this case are directed to sitagliptin dihydrogenphosphate (``sitagliptin DHP''), a dipeptidyl peptidase-IV (``DP-IV'') inhibito......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (2)
SYNOPSIS A representative claim at issue in this decision recites a pharmaceutical composition comprising, inter alia, a formulation stabilizer (PVP K......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (4)
In this case the Federal Circuit granted the accused infringers' petition for panel rehearing, vacated its prior decision, and reversed the district c......
期刊： BIOTECHNOLOGY LAW REPORT, 2022; 41 (1)
Moderna has sublicensed multiple patents owned by Arbutus relating to stable nucleic acid-lipid particles (SNALP), a nucleic acid delivery system usef......
